TARGETING RAS-PI3K SIGNALLING TO RE-EDUCATE THE STROMA OF RAS MUTANT LUNG CANCER.

Lung cancer is the leading cause of cancer-related death worldwide. Non-small lung cancer (NSCLC), the most prevalent form of lung cancer (85% of cases), has a dismal ten-year survival rate of 5%. KRAS is aberrantly activated by mutations in 30% of NSCLC. Patients harbouring this mutation have an even worst prognosis and currently there are no therapies available in the clinic. Thus, there is a strong clinical need to understand the molecular biology of KRAS-drive